LONDON, Ontario--(BUSINESS WIRE)--Trudell Medical International is pleased to announce the FDA approval of Alvesco® (ciclesonide) inhalation aerosol in combination with the AEROCOUNT® Dose Indicator. Alvesco, a novel inhaled corticosteroid, will be distributed in the U.S. by Sepracor Inc. under an agreement with Nycomed based in Europe.
